Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Minimal residual disease testing after stem cell transplantation for multiple myeloma. Bone Marrow Transplant 2016 Jan;51(1):2-12 PMID: 26191950

Pubmed ID

26191950

Abstract

Increased use of novel agents and autologous stem cell transplantation has led to a significant improvement in PFS and overall survival in patients with multiple myeloma. Despite improved treatment strategies, most patients eventually relapse due to persistent low levels of disease in the bone marrow. Increasingly sensitive methods to measure or detect such disease have been evaluated, including multi-parametric flow cytometry, PCR, next-generation sequencing and imaging modalities. The following literature review examines current methods for detecting and monitoring minimal or measurable residual disease (MRD) in the post-transplant setting. Improved methods for detecting MRD will refine the current definitions of remission and could guide treatment approaches.

Author List

Sherrod AM, Hari P, Mosse CA, Walker RC, Cornell RF

Author

Parameswaran Hari MD Chief, Professor in the Medicine department at Medical College of Wisconsin




Scopus

2-s2.0-84953346101   14 Citations

MESH terms used to index this publication - Major topics in bold

Animals
Autografts
High-Throughput Nucleotide Sequencing
Humans
Multiple Myeloma
Multiplex Polymerase Chain Reaction
Neoplasm, Residual
Stem Cell Transplantation
jenkins-FCD Prod-300 626508253d14e4184314fb9f66322a03a5906796